This is a preview of subscription content, log in via an institution to check access.
Notes
Unrestricted support for the study was provided by Genentech, Inc., to VeriTech Corporation.
Reference
Garrison LP Jr, et al. Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status. Cancer : 17 Jun 2013. Available from: URL: http://dx.doi.org/10.1002/cncr.28196
Rights and permissions
About this article
Cite this article
Retesting for HER2 in early breast cancer worth its cost. PharmacoEcon Outcomes News 682, 7 (2013). https://doi.org/10.1007/s40274-013-0543-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0543-y